Cronos Group (7CI) Stock Overview
A cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 7CI from our risk checks.
7CI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
Cronos Group Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$2.13 |
| 52 Week High | CA$3.06 |
| 52 Week Low | CA$1.43 |
| Beta | 1.2 |
| 1 Month Change | -3.28% |
| 3 Month Change | -6.43% |
| 1 Year Change | 41.54% |
| 3 Year Change | 23.25% |
| 5 Year Change | -69.29% |
| Change since IPO | -6.01% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7CI | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 1.7% | 2.1% | 2.3% |
| 1Y | 41.5% | 26.5% | 12.0% |
Return vs Industry: 7CI exceeded the German Pharmaceuticals industry which returned 26.5% over the past year.
Return vs Market: 7CI exceeded the German Market which returned 12% over the past year.
Price Volatility
| 7CI volatility | |
|---|---|
| 7CI Average Weekly Movement | 5.1% |
| Pharmaceuticals Industry Average Movement | 4.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in DE Market | 14.2% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: 7CI has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 7CI's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 610 | Mike Gorenstein | thecronosgroup.com |
Cronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. It offers dried flowers, pre-rolls, oils, vaporizers, edibles, and tinctures under the Spinach, Lord Jones, Lit, and Peace Naturals brand names. The company is headquartered in Stayner, Canada.
Cronos Group Inc. Fundamentals Summary
| 7CI fundamental statistics | |
|---|---|
| Market cap | €849.43m |
| Earnings (TTM) | -€8.18m |
| Revenue (TTM) | €126.99m |
Is 7CI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7CI income statement (TTM) | |
|---|---|
| Revenue | US$146.59m |
| Cost of Revenue | US$88.19m |
| Gross Profit | US$58.40m |
| Other Expenses | US$67.85m |
| Earnings | -US$9.45m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.025 |
| Gross Margin | 39.84% |
| Net Profit Margin | -6.44% |
| Debt/Equity Ratio | 0% |
How did 7CI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/07 21:03 |
| End of Day Share Price | 2026/04/02 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cronos Group Inc. is covered by 16 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jesse Pytlak | ATB Cormark Historical (Cormark Securities) |
| Vahan Ajamian | Beacon Securities Limited |
| Nadine Sarwat | Bernstein |